SinoMab Bioscience Ltd.
0.13
EUR
0.00
(0.00%)
ISIN
HK0000544194
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Shui On Leung
- Full Time Employees
- 95
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No.15 Science Park West Avenue Hong Kong Hong Kong
- IPO Date
- Nov 12, 2019
- Website
- sinomab.com
- Similar Companies
- Business
- SinoMab BioScience Limited is a clinical-stage biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of monoclonal antibody (mAb)-based biologics targeting immunological diseases. Its core product portfolio includes therapeutic antibodies for rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome, non-Hodgkin’s lymphoma, asthma, atopic dermatitis, Alzheimer's disease, vitiligo, alopecia areata, and osteoporosis. The company’s flagship product, SM03 (Suciraslimab), is a first-in-target monoclonal antibody for rheumatoid arthritis and other immune-related indications. SinoMab operates a production base in Haikou, Hainan, and is constructing a second facility in Suzhou, Jiangsu, for scalable manufacturing. Its drug discovery platforms include B-cell Therapeutic Platform, Alarmins-pathway Therapeutic Platform, Selective-T Cell Therapeutic Platform, Neurological Disease Platform, and Antibody Framework-Patching Humanisation Platform, enabling broad immunological therapeutic development. Founded in 2001 and headquartered in Hong Kong Science Park, SinoMab serves markets primarily in Greater China with expanding global partnerships. Recent major developments include the acceptance of its Biologics License Application (BLA) by China’s National Medical Products Administration (NMPA) for Suciraslimab, with expected commercialization within 12-18 months. The company completed GMP inspections at its Haikou production base in January 2024, a critical step for regulatory approval. In August 2025, SinoMab entered into a comprehensive strategic cooperation agreement to accelerate development and commercialization initiatives. SinoMab actively pursues global collaboration and licensing opportunities to expand its innovative therapeutic offerings for unmet medical needs in immunology. SinoMab's business segments encompass drug discovery, clinical trials, manufacturing, and commercialization, with revenues currently derived mainly from Hong Kong and the Chinese market. Its strategic focus on monoclonal antibodies and immune system modulation positions it in the biotechnology and healthcare sectors. SinoMab leverages strong in-house capabilities across antibody re-engineering, cell line development, bioprocessing, and preclinical studies, supporting a full drug development pipeline to deliver novel, patient-centric biologics. SinoMab’s recent advancements emphasize strengthening its product pipeline with first-in-class assets such as SM17, for treating moderate-to-severe atopic dermatitis, which reported positive phase 1B clinical trial results in China. The company also pursues immunotherapy candidates for autoimmune and inflammatory diseases backed by robust proprietary technologies aimed at expanding treatment options beyond conventional therapies. In summary, SinoMab BioScience Limited, founded in 2001 and headquartered in Hong Kong, develops and manufactures a diversified portfolio of monoclonal antibody therapeutics targeting immunological diseases, supported by scalable production facilities and cutting-edge drug development platforms. The company is transitioning from clinical-stage to commercialization, marked by regulatory milestones, enhanced production capacity, and strategic partnerships designed to accelerate growth in the global biopharmaceutical industry.